CUBT:NYE-Curative Biotechnology Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.0192

Change

+0.00 (+6.08)%

Market Cap

USD 0.02B

Volume

2.75K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NVO Novo Nordisk A/S

+0.01 (+0.01%)

USD 602.60B
BHVN Biohaven Pharmaceutical Holdin..

+0.42 (+1.26%)

USD 2.95B
HTD John Hancock Tax Advantaged Di..

-0.19 (-0.94%)

USD 2.41B
RCUS Arcus Biosciences Inc

-0.03 (-0.18%)

USD 1.41B
DNA Ginkgo Bioworks Holdings

-0.01 (-2.66%)

USD 1.15B
NUVB Nuvation Bio Inc

+0.03 (+1.00%)

USD 0.72B
PGP PIMCO Global StocksPLUS & Inco..

-0.09 (-1.19%)

USD 0.32B
ADCT ADC Therapeutics SA

+0.14 (+4.43%)

USD 0.30B
ATNM Actinium Pharmaceuticals Inc

-0.20 (-2.49%)

USD 0.24B
CYBN Cybin Inc

N/A

USD 0.22B

ETFs Containing CUBT

MKC:CA Mackenzie Maximum Diversi.. 0.00 % 0.59 %

-0.19 (-0.56%)

CAD 0.43B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.86% 46% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.86% 46% F 12% F
Trailing 12 Months  
Capital Gain 37.14% 73% C 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.14% 73% C 83% B
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 148.60% 97% N/A 98% N/A
Dividend Return 148.60% 97% N/A 98% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 2,520.54% 7% C- 1% F
Risk Adjusted Return 5.90% 57% F 30% F
Market Capitalization 0.02B 28% F 9% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector